Consun Pharmaceutical Group Overview
- Year Founded
-
1997
- Status
-
Public
- Employees
-
3,178
- Stock Symbol
-
01681
- Investments
-
2
- Share Price
-
$0.76
- (As of Tuesday Closing)
Consun Pharmaceutical Group General Information
Description
Consun Pharmaceutical Group Ltd is a biotechnology company with a modern pharmaceutical enterprise that integrates R&D, production, and marketing. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Consun derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.
Contact Information
Website
www.chinaconsun.comCorporate Office
- 71, Dongpeng Avenue Eastern section
- Guangzhou Economic and Technological Development D
- Guangzhou, Guangdong 510760
- China
Corporate Office
- 71, Dongpeng Avenue Eastern section
- Guangzhou Economic and Technological Development D
- Guangzhou, Guangdong 510760
- China
Consun Pharmaceutical Group Stock Performance
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.76 | $0.76 | $0.55 - $0.92 | $632M | 826M | 3.45M | $0.15 |
Consun Pharmaceutical Group Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 195,814 | 172,906 | 168,561 | 284,133 |
| Revenue | 380,605 | 366,100 | 347,411 | 316,654 |
| EBITDA | 120,548 | 126,382 | 116,009 | 114,991 |
| Net Income | 116,225 | 110,890 | 101,404 | 91,399 |
| Total Assets | 777,021 | 709,113 | 684,448 | |
| Total Debt | 0 | 72,163 | 66,699 | 95,852 |
Consun Pharmaceutical Group Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Consun Pharmaceutical Group Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Consun Pharmaceutical Group Executive Team (4)
| Name | Title | Board Seat |
|---|---|---|
| Li Qian | Co-Founder, Chief Executive Officer, President & Vice Chairman | |
| Zhu Quan | Chief Scientific Officer & Executive Director | |
| Peicheng Fang | Vice President & Executive Director | |
| An Meng | Chairman |
Consun Pharmaceutical Group Board Members (3)
| Name | Representing | Role | Since |
|---|---|---|---|
| 00 0000 | Consun Pharmaceutical Group | Chairman | 000 0000 |
Consun Pharmaceutical Group Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Consun Pharmaceutical Group Investments & Acquisitions (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Guangxi Yulin Pharmaceutical | 16-Aug-2016 | 000000000 | 000.00 | Drug Discovery | |
| Guangxi Yulin Pharmaceutical | 09-Nov-2015 | Merger/Acquisition | 00000 | Drug Discovery |
Consun Pharmaceutical Group Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Guangxi Yulin Pharmaceutical | Drug Discovery | Yulin, China | 0000 |
Consun Pharmaceutical Group ESG
Risk Overview
Risk Rating
Updated March, 01, 2024
28.81 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 16,009
Rank
Percentile
Pharmaceuticals
Industry
00 of 909
Rank
Percentile
Pharmaceuticals
Subindustry
00 of 446
Rank
Percentile
Consun Pharmaceutical Group FAQs
-
When was Consun Pharmaceutical Group founded?
Consun Pharmaceutical Group was founded in 1997.
-
Who is the founder of Consun Pharmaceutical Group?
Li Qian is the founder of Consun Pharmaceutical Group.
-
Who is the CEO of Consun Pharmaceutical Group?
Li Qian is the CEO of Consun Pharmaceutical Group.
-
Where is Consun Pharmaceutical Group headquartered?
Consun Pharmaceutical Group is headquartered in Guangzhou, China.
-
What is the size of Consun Pharmaceutical Group?
Consun Pharmaceutical Group has 3,178 total employees.
-
What industry is Consun Pharmaceutical Group in?
Consun Pharmaceutical Group’s primary industry is Drug Discovery.
-
Is Consun Pharmaceutical Group a private or public company?
Consun Pharmaceutical Group is a Public company.
-
What is Consun Pharmaceutical Group’s stock symbol?
The ticker symbol for Consun Pharmaceutical Group is 01681.
-
What is the current stock price of Consun Pharmaceutical Group?
As of 17-Sep-2024 the stock price of Consun Pharmaceutical Group is $0.76.
-
What is the current market cap of Consun Pharmaceutical Group?
The current market capitalization of Consun Pharmaceutical Group is $632M.
-
What is Consun Pharmaceutical Group’s current revenue?
The trailing twelve month revenue for Consun Pharmaceutical Group is $381M.
-
What is Consun Pharmaceutical Group’s annual earnings per share (EPS)?
Consun Pharmaceutical Group’s EPS for 12 months was $0.15.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
